Belite Bio to Participate in Three Upcoming Investor Conferences

Rhea-AI Summary

Belite Bio (NASDAQ: BLTE), a clinical-stage biopharmaceutical company focusing on degenerative retinal diseases, has announced its participation in three upcoming investor conferences. The executive management team will attend:

1. H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9, 2024, at 9:30 am ET for a fireside chat.

2. 2024 Cantor Global Healthcare Conference in New York on September 18, 2024, at 3:40 pm ET for a corporate presentation.

3. Deutsche Bank Depositary Receipts Virtual Investor Conference on September 25, 2024, at 11:00 am ET for a virtual corporate presentation.

Webcasts of all presentations will be available on Belite Bio's investor relations website and archived for 90 days after each event.

SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in three upcoming investor conferences. Details for the presentations are as follows:

• H.C. Wainwright 26^th Annual Global Investment Conference (New York, New York)
  • September 9, 2024, at 9:30 am ET, fireside chat
• 2024 Cantor Global Healthcare Conference (New York, New York)
  • September 18, 2024, at 3:40 pm ET, corporate presentation
• Deutsche Bank Depositary Receipts Virtual Investor Conference (Virtual)
  • September 25, 2024, at 11:00 am ET, corporate presentation

A webcast of each presentation can be accessed under the "Events" tab on the investor relations section of the Belite Bio website at: https://investors.belitebio.com/presentations-events/events. The replays will be archived for 90 days following the presentation date.

About Belite Bio
Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases that have significant unmet medical needs such as (i) atrophic age-related macular degeneration (AMD), commonly known as Geographic Atrophy (GA) in advanced dry AMD, and (ii) autosomal recessive Stargardt disease type 1, or STGD1, in addition to specific metabolic diseases. For more information, follow us on Twitter, Instagram, LinkedIn, Facebook, or visit us at www.belitebio.com.

Media and Investor Relations Contact:

Jennifer Wu
ir@belitebio.com

Julie Fallon
belite@argotpartners.com

FAQ

What investor conferences will Belite Bio (BLTE) attend in September 2024?

Belite Bio will attend three investor conferences in September 2024: H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024 Cantor Global Healthcare Conference on September 18, 2024, and Deutsche Bank Depositary Receipts Virtual Investor Conference on September 25, 2024.

When and where is Belite Bio's (BLTE) presentation at the H.C. Wainwright conference?

Belite Bio will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, at 9:30 am ET in New York, New York.

What type of presentation will Belite Bio (BLTE) give at the Cantor Global Healthcare Conference?

Belite Bio will deliver a corporate presentation at the 2024 Cantor Global Healthcare Conference on September 18, 2024, at 3:40 pm ET in New York, New York.

How can investors access Belite Bio's (BLTE) conference presentations?

Investors can access webcasts of Belite Bio's presentations under the 'Events' tab on the investor relations section of the company's website at https://investors.belitebio.com/presentations-events/events. The replays will be archived for 90 days following each presentation.